$CERS
Cerus Corp

2013 Q1 Form 10-Q Financial Statement

#000119312513198807 Filed on May 03, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q1
Revenue $9.733M $8.691M
YoY Change 11.99% 40.56%
Cost Of Revenue $5.090M $5.514M
YoY Change -7.69% 56.25%
Gross Profit $4.643M $3.177M
YoY Change 46.14% 19.71%
Gross Profit Margin 47.7% 36.56%
Selling, General & Admin $6.853M $5.966M
YoY Change 14.87% 7.92%
% of Gross Profit 147.6% 187.79%
Research & Development $2.700M $1.824M
YoY Change 48.03% 0.88%
% of Gross Profit 58.15% 57.41%
Depreciation & Amortization $167.0K $208.0K
YoY Change -19.71% -22.96%
% of Gross Profit 3.6% 6.55%
Operating Expenses $9.603M $7.840M
YoY Change 22.49% 6.15%
Operating Profit -$4.960M -$4.572M
YoY Change 8.49% 6.42%
Interest Expense $131.0K $139.0K
YoY Change -5.76%
% of Operating Profit
Other Income/Expense, Net -$5.241M -$4.227M
YoY Change 23.99% 442.62%
Pretax Income -$10.20M -$8.799M
YoY Change 15.93% 73.38%
Income Tax $51.00K $35.00K
% Of Pretax Income
Net Earnings -$10.25M -$8.834M
YoY Change 16.05% 73.28%
Net Earnings / Revenue -105.33% -101.65%
Basic Earnings Per Share -$0.17 -$0.17
Diluted Earnings Per Share -$0.17 -$0.17
COMMON SHARES
Basic Shares Outstanding 59.73M shares 53.09M shares
Diluted Shares Outstanding 59.73M shares 53.09M shares

Balance Sheet

Concept 2013 Q1 2012 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $69.20M $31.50M
YoY Change 119.68% 29.1%
Cash & Equivalents $69.16M $31.45M
Short-Term Investments $9.000M
Other Short-Term Assets $418.0K $1.100M
YoY Change -62.0% -8.33%
Inventory $11.76M $8.900M
Prepaid Expenses $1.370M
Receivables $4.733M $5.000M
Other Receivables $0.00 $0.00
Total Short-Term Assets $87.44M $46.60M
YoY Change 87.64% 17.97%
LONG-TERM ASSETS
Property, Plant & Equipment $1.595M $1.900M
YoY Change -16.05% -17.39%
Goodwill $1.316M
YoY Change
Intangibles $1.496M
YoY Change
Long-Term Investments
YoY Change
Other Assets $58.00K $500.0K
YoY Change -88.4% -28.57%
Total Long-Term Assets $4.767M $5.400M
YoY Change -11.72% -12.9%
TOTAL ASSETS
Total Short-Term Assets $87.44M $46.60M
Total Long-Term Assets $4.767M $5.400M
Total Assets $92.21M $52.00M
YoY Change 77.32% 13.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.887M $4.200M
YoY Change -7.45% -19.23%
Accrued Expenses $8.149M $7.500M
YoY Change 8.65% 38.89%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.500M $3.100M
YoY Change 45.16% 72.22%
Total Short-Term Liabilities $27.66M $27.40M
YoY Change 0.93% 22.87%
LONG-TERM LIABILITIES
Long-Term Debt $2.500M $4.100M
YoY Change -39.02% 51.85%
Other Long-Term Liabilities $1.209M $1.200M
YoY Change 0.75% -25.0%
Total Long-Term Liabilities $1.209M $5.300M
YoY Change -77.19% 23.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $27.66M $27.40M
Total Long-Term Liabilities $1.209M $5.300M
Total Liabilities $31.42M $32.70M
YoY Change -3.92% 22.93%
SHAREHOLDERS EQUITY
Retained Earnings -$470.1M
YoY Change
Common Stock $70.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $60.79M $19.30M
YoY Change
Total Liabilities & Shareholders Equity $92.21M $52.00M
YoY Change 77.32% 13.79%

Cashflow Statement

Concept 2013 Q1 2012 Q1
OPERATING ACTIVITIES
Net Income -$10.25M -$8.834M
YoY Change 16.05% 73.28%
Depreciation, Depletion And Amortization $167.0K $208.0K
YoY Change -19.71% -22.96%
Cash From Operating Activities -$8.352M -$3.904M
YoY Change 113.93% -22.85%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $2.000K
YoY Change -100.0% -99.05%
Cash From Investing Activities -$26.00K $196.0K
YoY Change -113.27% 22.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $51.50M $9.612M
YoY Change 435.81%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 50.85M 9.660M
YoY Change 426.35% -2246.67%
NET CHANGE
Cash From Operating Activities -8.352M -3.904M
Cash From Investing Activities -26.00K 196.0K
Cash From Financing Activities 50.85M 9.660M
Net Change In Cash 42.47M 5.952M
YoY Change 613.49% -211.25%
FREE CASH FLOW
Cash From Operating Activities -$8.352M -$3.904M
Capital Expenditures -$30.00K $0.00
Free Cash Flow -$8.322M -$3.904M
YoY Change 113.17% -22.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
69716000 shares
CY2012Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
10976000
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-470104000
CY2013Q1 us-gaap Assets
Assets
92207000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.43
CY2013Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
400000
CY2013Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
302000
CY2013Q1 us-gaap Cost Method Investments Aggregate Carrying Amount
CostMethodInvestmentsAggregateCarryingAmount
0
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69163000
CY2013Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2017000
CY2013Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Obligations
FairValueLiabilitiesMeasuredOnRecurringBasisObligations
10976000
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31449000
CY2013Q1 us-gaap Secured Long Term Debt
SecuredLongTermDebt
2485000
CY2013Q1 us-gaap Goodwill
Goodwill
1316000
CY2013Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6995000
CY2013Q1 us-gaap Other Assets Current
OtherAssetsCurrent
418000
CY2013Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3865000
CY2013Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
58000
CY2013Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1334000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
200000
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
60788000
CY2013Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1496000
CY2013Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
53569000
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2734000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
200000
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1450000
CY2013Q1 us-gaap Secured Debt
SecuredDebt
6955000
CY2013Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
40000
CY2013Q1 us-gaap Inventory Finished Goods And Work In Process Net Of Reserves
InventoryFinishedGoodsAndWorkInProcessNetOfReserves
11756000
CY2013Q1 us-gaap Liabilities
Liabilities
31419000
CY2013Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3887000
CY2013Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1370000
CY2013Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
174000
CY2013Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1209000
CY2013Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
69000
CY2013Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4733000
CY2013Q1 us-gaap Inventory Net
InventoryNet
11756000
CY2013Q1 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
0
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92207000
CY2013Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1496000
CY2013Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4722000
CY2013Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12800000 shares
CY2013Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8149000
CY2013Q1 us-gaap Secured Debt Current
SecuredDebtCurrent
4470000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
200000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
200000
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
27656000
CY2013Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
10976000
CY2013Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7891000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10663000 shares
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
70000
CY2013Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
521000
CY2013Q1 us-gaap Assets Current
AssetsCurrent
87440000
CY2013Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
150000
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1595000
CY2013Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
530822000
CY2013Q1 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
53569000
CY2013Q1 cers Longterm Debt Maturities Repayments Of Principal In Year One
LongtermDebtMaturitiesRepaymentsOfPrincipalInYearOne
1541000
CY2013Q1 cers Finite Lived Intangible Assets Amortization Expense Year Six
FiniteLivedIntangibleAssetsAmortizationExpenseYearSix
200000
CY2013Q1 cers Accrued Inventory
AccruedInventory
3965000
CY2013Q1 cers Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
4 Customer
CY2013Q1 cers Cumulative Outstanding Trade Receivables Major Customers Percentage
CumulativeOutstandingTradeReceivablesMajorCustomersPercentage
0.63 pure
CY2013Q1 cers Debt Instrument Unamortized Noncurrent
DebtInstrumentUnamortizedNoncurrent
15000
CY2013Q1 cers Debt Instrument Unamortized Current
DebtInstrumentUnamortizedCurrent
25000
CY2013Q1 cers Debt Instrument Carrying Non Current
DebtInstrumentCarryingNonCurrent
2500000
CY2013Q1 cers Debt Instrument Carrying Current
DebtInstrumentCarryingCurrent
4495000
CY2013Q1 cers Finite Lived Intangible Assets Amortization Expense Year Seven
FiniteLivedIntangibleAssetsAmortizationExpenseYearSeven
200000
CY2013Q1 cers Leasehold Improvement Reflected In Accrued Liabilities
LeaseholdImprovementReflectedInAccruedLiabilities
100000
CY2013Q1 cers Options And Other Stock Based Awards
OptionsAndOtherStockBasedAwards
10700000 shares
CY2013Q1 cers Finite Lived Intangible Assets Amortization Expense Year Eight
FiniteLivedIntangibleAssetsAmortizationExpenseYearEight
100000
CY2013Q1 cers Leasehold Improvement Reflected In Other Non Current Liabilities
LeaseholdImprovementReflectedInOtherNonCurrentLiabilities
700000
CY2013Q1 cers Outstanding Liability Related To Leasehold Improvements Current And Non Current
OutstandingLiabilityRelatedToLeaseholdImprovementsCurrentAndNonCurrent
800000
CY2013Q1 cers Performance Based Stock Options Outstanding
PerformanceBasedStockOptionsOutstanding
50000 shares
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25497000
CY2012Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
2896000
CY2012Q4 us-gaap Goodwill
Goodwill
1316000
CY2012Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
7773000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2038000
CY2012Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
3551000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
59000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
19107000
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1546000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
10268000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2575000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2692000
CY2012Q4 us-gaap Secured Debt
SecuredDebt
7724000
CY2012Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
49000
CY2012Q4 us-gaap Inventory Finished Goods And Work In Process Net Of Reserves
InventoryFinishedGoodsAndWorkInProcessNetOfReserves
10180000
CY2012Q4 us-gaap Liabilities
Liabilities
29812000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7186000
CY2012Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
638000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
77000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1241000
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
5903000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-459852000
CY2012Q4 us-gaap Assets
Assets
48919000
CY2010 cers Proceeds From Landlord Financing Leasehold Improvement
ProceedsFromLandlordFinancingLeaseholdImprovement
1100000
CY2012 us-gaap Inventory Write Down
InventoryWriteDown
1700000
CY2012 cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
3600000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.40
CY2012Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
300000
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
62000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4444000
CY2012Q4 us-gaap Inventory Net
InventoryNet
10180000
CY2012Q4 us-gaap Availableforsale Securities Gross Unrealized Gain
AvailableforsaleSecuritiesGrossUnrealizedGain
0
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48919000
CY2012Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
304000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26696000
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2017000
CY2012Q4 us-gaap Fair Value Liabilities Measured On Recurring Basis Obligations
FairValueLiabilitiesMeasuredOnRecurringBasisObligations
5903000
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1546000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7619000
CY2012Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
4828000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25613000
CY2012Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
5903000
CY2012Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
6629000
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8504000 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
56000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
471000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
43996000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1698000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
478903000
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
10268000
CY2012Q4 cers Accrued Inventory
AccruedInventory
2352000
CY2012Q4 cers Cumulative Outstanding Trade Receivables Number Of Major Customers
CumulativeOutstandingTradeReceivablesNumberOfMajorCustomers
3 Customer
CY2012Q4 cers Cumulative Outstanding Trade Receivables Major Customers Percentage
CumulativeOutstandingTradeReceivablesMajorCustomersPercentage
0.59 pure
CY2012Q4 cers Debt Instrument Unamortized Noncurrent
DebtInstrumentUnamortizedNoncurrent
20000
CY2012Q4 cers Debt Instrument Unamortized Current
DebtInstrumentUnamortizedCurrent
29000
CY2012Q4 cers Debt Instrument Carrying Non Current
DebtInstrumentCarryingNonCurrent
2916000
CY2012Q4 cers Debt Instrument Carrying Current
DebtInstrumentCarryingCurrent
4857000
CY2013Q1 dei Trading Symbol
TradingSymbol
CERS
CY2013Q1 dei Entity Registrant Name
EntityRegistrantName
CERUS CORP
CY2013Q1 dei Amendment Flag
AmendmentFlag
false
CY2013Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2013Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013Q1 dei Document Type
DocumentType
10-Q
CY2013Q1 dei Document Period End Date
DocumentPeriodEndDate
2013-03-31
CY2013Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001020214
CY2013Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2013Q1 us-gaap Reclassifications
Reclassifications
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Reclassification</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain amounts from the prior period relating to &#x2018;&#x2018;Foreign exchange gain (loss)&#x2019;&#x2019; and &#x2018;&#x2018;Provision for income taxes&#x2019;&#x2019; have been reclassified from &#x2018;&#x2018;Other income, net&#x2019;&#x2019; to conform to the current period presentation.</font></p> </div>
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4960000
CY2013Q1 us-gaap Revenue From Grants
RevenueFromGrants
0
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
9733000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3299000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
51502000
CY2013Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17000
CY2013Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-56000
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10252000
CY2013Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.91
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
43000 shares
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
167000
CY2013Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
526000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
713000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.58
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.98
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
The restricted stock units generally vest in three annual installments from the date of grant and are generally issuable at the end of the three-year vesting term.
CY2013Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P10Y
CY2013Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2700000
CY2013Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
67000 shares
CY2013Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2013Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
0
CY2013Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Concentration of Credit Risk</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Pursuant to the Company&#x2019;s investment policy, substantially all of the Company&#x2019;s cash, and cash equivalents are maintained at a major financial institution of high credit standing. The Company monitors the financial credit worthiness of the issuers of its investments and limits the concentration in individual securities and types of investments that exist within its investment portfolio. Generally, all of the Company&#x2019;s investments carry high credit quality ratings, which is in accordance with its investment policy. At March&#xA0;31, 2013, the Company does not believe there is significant financial risk from non-performance by the issuers of the Company&#x2019;s cash equivalents.</font></p> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"> &#xA0;</p> <p style="MARGIN-TOP: 0px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Concentrations of credit risk with respect to trade receivables exist. However, in connection with the Company&#x2019;s revolving line of credit, as discussed in Note 8 in the Notes to Condensed Consolidated Financial Statements, the Company purchased a credit insurance policy that mitigates some of its credit risk, as the policy will pay either the Company or its lender on eligible claims filed on its outstanding receivables. On a regular basis, including at the time of sale, the Company performs credit evaluations of its customers. Generally, the Company does not require collateral from its customers to secure accounts receivable. To the extent that the Company determines specific invoices or customer accounts may be uncollectible, the Company reserves against the accounts receivable on its condensed consolidated balance sheets and records a charge on its condensed consolidated statements of operations.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company had four customers and three customers that accounted for more than 10% of the Company&#x2019;s outstanding trade receivables at March&#xA0;31, 2013, and December&#xA0;31, 2012, respectively. These customers cumulatively represented approximately 63% and 59% of the Company&#x2019;s outstanding trade receivables at March&#xA0;31, 2013, and December&#xA0;31, 2012, respectively. To date, the Company has not experienced collection difficulties from these customers.</font></p> </div>
CY2013Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
4000
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8352000
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-26000
CY2013Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
26000
CY2013Q1 us-gaap Goodwill Other Changes
GoodwillOtherChanges
0
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
97000
CY2013Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.23
CY2013Q1 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Guarantee and Indemnification Arrangements</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company recognizes the fair value for guarantee and indemnification arrangements issued or modified by the Company after December&#xA0;31, 2002. In addition, the Company monitors the conditions that are subject to the guarantees and indemnifications in order to identify if a loss has occurred. If the Company determines it is probable that a loss has occurred, then any such estimable loss would be recognized under those guarantees and indemnifications. Some of the agreements that the Company is a party to contain provisions that indemnify the counter party from damages and costs resulting from claims that the Company&#x2019;s technology infringes the intellectual property rights of a third party or claims that the sale or use of the Company&#x2019;s products have caused personal injury or other damage or loss. The Company has not received any such requests for indemnification under these provisions and has not been required to make material payments pursuant to these provisions.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company generally provides for a one-year warranty on certain of its INTERCEPT blood-safety products covering defects in materials and workmanship. The Company accrues costs associated with warranty obligations when claims become known and are estimable. During the year ended December 31, 2012, the Company provided for warranty obligations related to replacement costs for certain of its products that the Company identified were defective or had the potential of being defective. In connection with the warranty obligations provided for in relation to certain of its products during the year ended December 31, 2012, the Company filed a warranty claim against Fresenius, which Fresenius accepted. As a result, the Company recorded a current asset of $1.8 million on its consolidated balance sheets as of December 31, 2012 representing the full amount of the warranty claim against Fresenius as Fresenius will supply the Company with replacement products or credit notes for those defective or potentially defective products. The Company also wrote-down the value of certain unsalable inventory of $1.7 million related to these products as an offsetting warranty claim against Fresenius as of December 31, 2012. As of March 31, 2013, the Company&#x2019;s warranty claim against Fresenius is $0.3 million and all unsalable inventory has been returned. During the three months ended March&#xA0;31, 2013, the Company identified a separate production defect related to unsold inventory. The Company&#x2019;s third party manufacturer has taken responsibility for the cost of replacing such damaged goods, therefore, the Company has borne no costs associated with these defects. Prior to these incidents, there have been very few warranty costs incurred. As a result, the Company had not accrued for any potential future warranty costs at March&#xA0;31, 2013. In addition, the Company believes that the defective products and those that had the potential of being defective identified during the year ended December&#xA0;31, 2012 are isolated.</font></p> </div>
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
42467000
CY2013Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-910000
CY2013Q1 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
1335000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2299000 shares
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59730000 shares
CY2013Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2013Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
5073000
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
289000
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-10201000
CY2013Q1 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
26000
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50845000
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
30000 shares
CY2013Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
9603000
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59730000 shares
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1624000
CY2013Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5090000
CY2013Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
CY2013Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
713000
CY2013Q1 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2013Q1 us-gaap Gross Profit
GrossProfit
4643000
CY2013Q1 us-gaap Interest Paid
InterestPaid
78000
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
7000
CY2013Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15531000 shares
CY2013Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
152000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-10252000
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5241000
CY2013Q1 us-gaap Availableforsale Securities Gross Realized Losses Excluding Other Than Temporary Impairments
AvailableforsaleSecuritiesGrossRealizedLossesExcludingOtherThanTemporaryImpairments
0
CY2013Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-54000
CY2013Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6853000
CY2013Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
85000
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
51000
CY2013Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2013Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Use of Estimates</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements requires management to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates, which are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</font></p> </div>
CY2013Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
50000
CY2013Q1 us-gaap Interest Expense
InterestExpense
131000
CY2013Q1 cers Reclassification To Prepaid Expenses From Inventory
ReclassificationToPrepaidExpensesFromInventory
400000
CY2013Q1 cers Reclassification To Accounts Payable From Inventory
ReclassificationToAccountsPayableFromInventory
500000
CY2012Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2012Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4572000
CY2012Q1 us-gaap Revenue From Grants
RevenueFromGrants
91000
CY2013Q1 cers Eligible To Receive Royalty Fee
EligibleToReceiveRoyaltyFee
0.01 pure
CY2013Q1 cers Expiration Of Non Cancelable Operating Leases Maximum Year
ExpirationOfNonCancelableOperatingLeasesMaximumYear
2019
CY2013Q1 cers Inventory Life Finished Goods Period
InventoryLifeFinishedGoodsPeriod
P2Y
CY2013Q1 cers Payment For Royalty
PaymentForRoyalty
800000
CY2013Q1 cers Payment For Manufacturing Of Entity Products
PaymentForManufacturingOfEntityProducts
3900000
CY2013Q1 cers Minimum Term Of Non Cancelable Operating Leases
MinimumTermOfNonCancelableOperatingLeases
P1Y
CY2013Q1 cers Safety Product Warranty Period
SafetyProductWarrantyPeriod
P1Y
CY2013Q1 cers Warrant Liability Revaluation Gain Loss
WarrantLiabilityRevaluationGainLoss
-5073000
CY2013Q1 cers Performance Based Stock Options Awards
PerformanceBasedStockOptionsAwards
0
CY2013Q1 cers Work In Process Inventory Life Period
WorkInProcessInventoryLifePeriod
P1Y
CY2012Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
8691000
CY2012Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-530000
CY2012Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9612000
CY2012Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2012Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2012Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8834000
CY2012Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
200000
CY2012Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
208000
CY2012Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0
CY2012Q1 us-gaap Share Based Compensation
ShareBasedCompensation
542000
CY2012Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2012Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1824000
CY2012Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2012Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
6000
CY2012Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3904000
CY2012Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
196000
CY2012Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
10000
CY2012Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
86000
CY2012Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5952000
CY2012Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
124000
CY2012Q1 us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
29000
CY2012Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53088000 shares
CY2012Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2012Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1074000
CY2012Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8799000
CY2012Q1 us-gaap Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
2000
CY2012Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2012Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9660000
CY2012Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2012Q1 us-gaap Operating Expenses
OperatingExpenses
7840000
CY2012Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53088000 shares
CY2012Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2467000
CY2012Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2012Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5514000
CY2012Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
2000
CY2012Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
542000
CY2012Q1 us-gaap Available For Sale Securities Gross Realized Gains
AvailableForSaleSecuritiesGrossRealizedGains
0
CY2012Q1 us-gaap Gross Profit
GrossProfit
3177000
CY2012Q1 us-gaap Interest Paid
InterestPaid
83000
CY2012Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2012Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14399000 shares
CY2012Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
77000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-8834000
CY2012Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4227000
CY2012Q1 us-gaap Availableforsale Securities Gross Realized Losses Excluding Other Than Temporary Impairments
AvailableforsaleSecuritiesGrossRealizedLossesExcludingOtherThanTemporaryImpairments
0
CY2012Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
371000
CY2012Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5966000
CY2012Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000
CY2012Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
50000
CY2012Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1674000
CY2012Q1 us-gaap Interest Expense
InterestExpense
139000
CY2012Q1 cers Payment For Royalty
PaymentForRoyalty
700000
CY2012Q1 cers Warrant Liability Revaluation Gain Loss
WarrantLiabilityRevaluationGainLoss
-4461000
CY2012Q1 cers Performance Based Stock Options Awards
PerformanceBasedStockOptionsAwards
0

Files In Submission

Name View Source Status
0001193125-13-198807-index-headers.html Edgar Link pending
0001193125-13-198807-index.html Edgar Link pending
0001193125-13-198807.txt Edgar Link pending
0001193125-13-198807-xbrl.zip Edgar Link pending
cers-20130331.xml Edgar Link completed
cers-20130331.xsd Edgar Link pending
cers-20130331_cal.xml Edgar Link unprocessable
cers-20130331_def.xml Edgar Link unprocessable
cers-20130331_lab.xml Edgar Link unprocessable
cers-20130331_pre.xml Edgar Link unprocessable
d510642d10q.htm Edgar Link pending
d510642dex311.htm Edgar Link pending
d510642dex312.htm Edgar Link pending
d510642dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending